肩痛散联合加味黄芪桂枝汤治疗肩周炎的临床疗效分析

Combination therapy of Jiantongsan and Astragalus Guizhitang for frozen shoulder

目的:研究肩痛散联合加味黄芪桂枝汤治疗肩周炎的临床应用效果。方法:选取2013年3月至2015年2月我科室收治疗的符合肩周炎诊断的患者60例,按随机数字表法分为治疗组和对照组各30例,治疗组给予肩痛散联合加味黄芪桂枝汤治疗,对照组给予单独加味黄芪桂枝汤治疗。分析比较两组治疗前后疼痛视觉模拟评分(VAS)、WOMAC量表积及IL-1及CRP指标的变化情况。结果:治疗3周后VAS评分:治疗组患者为(2.80±1.47)明显优于对照组(3.46±1.51)。WOMAC量表积分:治疗组患者为(24.36±3.47)明显优于对照组(36.85±4.11)。治疗组患者治疗后观测指标IL-1和CRP分别为(20.65±7.91pg/ml、11.62±4.58mg/L),均优于对照组(34.54±13.72pg/ml、17.08±5.01mg/L)。4治疗效果:治疗组治疗有效率90%明显高于对照组76.7%。结论:联合应用肩痛散及加味黄芪桂枝汤治疗肩周炎具有效果确切、治疗有效率高、无明显不良反应等特点。

Objective： To investigate the clinical effect of treatment of frozen shoulder with combination therapy of Jiantongsan and Astragalus Guizhitang. Methods： 60 patients diagnosed frozen shoulder from march 2013 to february 2015,randomly divided into treatment group and control group,the treatment group received the combination therapy of Jiantongsan and Astragalus Guizhitang,the control group was given Astragalus Guizhitang. Analysis were compared before and after the treatment of pain visual analogue scale（ VAS）,WOMAC scale changes accumulate and shoulder range of motion. Results： VAS scores after 3 weeks of treatment： the treatment group patients（ 2. 80 ± 1. 47） were better than the control group（ 3. 46 ± 1. 51）,and the difference was statistically significant（ p 0. 05）. WOMAC scale score： the treatment group patients（ 24. 36 ± 3. 47） were better than the control group（ 36. 85 ± 4. 11）,and the difference was statistically significant（ p 0.05）. Shoulder joint activity： the treatment group abduction,external rotation degrees（ 76. 41 ± 15. 27,19. 23 ± 4. 70） were better than the control group（ 60. 30 ± 14. 10,17. 10 ± 4. 55）,and the difference was statistically significant（ p 0. 05）. Treatment： The efficiency of treatment group about the treatment efficiency was 90% higher than 76. 7% of the control group,and the difference was statistically significant（ p 0. 05）. Conclusion： It has exact effect for the combination of Jiantongsan and Astragalus Guizhitang,and is worthy of further clinical application and research.